Survival data boosts Merck's Keytruda lead in lung cancer

(Reuters) - Merck& Co's immunotherapy Keytruda plus chemotherapy significantly improved overall survival in newly-diagnosed patients with advanced non-small cell lung cancer in a closely-watched study, cementing its lead position over Bristol-Myers Squibb Co and others in the most lucrative oncology market.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news